Valeant Pharmaceuticals International Inc. increased its takeover offer for Salix Pharmaceuticals Inc. to $10.96 billion in cash, eliminating Endo International Plc. as a contender as a contender, which was the only other bidder for the maker of gastrointestinal drugs.
The Morning Read provides a 24-hour wrap up of everything else healthcare’s innovators need to know about the business of medicine (and beyond). The author of The Read published it but all full-time MedCity News journalists contribute to its content. TOP STORIES GOP leaders are considering a vote next week on legislation that would abolish […]
AIDS patients expecting approval of a new HIV-associated diarrhea treatment in June must wait at least another three months for a decision. Salix Pharmaceuticals (NASDAQ:SLXP) had been scheduled for a June 5 decision date on its experimental diarrhea treatment crofelemer. But the Raleigh, North Carolina company said it has been notified by the U.S. Food […]
Salix Pharmaceuticals (NASDAQ:SLXP) must wait a little longer for a regulatory decision on its constipation treatment Relistor. An approval decision was expected on April 27. But the U.S. Food and Drug Administration has notified the Raleigh, North Carolina company that it needs more time. The new target date to issue an approval decision is July […]
Gastrointestinal treatments firm Salix Pharmaceuticals (NASDAQ:SLXP) aims to raise $600 million in debt financing. The Raleigh, North Carolina company has priced the $600 million offering of convertible senior notes, which is open to qualified institutional investors. Salix could raise up to $90 million more if purchasers exercise overallotment options. Interest on the notes will be […]
AIDS patients who frequently suffer from diarrhea may now finally see some light at the end of the tunnel for a new drug developed to help them. The U.S. Food and Drug Administration has granted priority review for Salix Pharmaceuticals‘ (NASDAQ:SLXP) crofelemer and an approval decision on the drug candidate could come by June 5. […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Salix Pharmaceuticals (NASDAQ:SLXP) is a step closer to bringing to the U.S. Food and Drug Administration a once-a-day pill version of injectable constipation drug Relistor. The Raleigh pharmaceutical company released successful phase 3 clinical trial results for the oral version of the drug and Salix now plans to submit a New Drug Application for the […]
Gastrointestinal therapeutics firm Salix Pharmaceuticals (NASDAQ:SLXP) is pressing ahead with a drug candidate to treat diarrhea in AIDS patients despite a deteriorating relationship with its drug partner that has led to a contract dispute and dueling lawsuits. Raleigh, North Carolina-based Salix today filed a New Drug Application for crofelemer, a filing that comes more than […]
The Salix Pharmaceuticals (NASDAQ:SLXP) irritable bowel syndrome drug candidate that failed to win U.S. Food and Drug Administration approval earlier this year is on its way to starting another phase 3 clinical trial. The Raleigh, North Carolina company said an FDA advisory committee has accepted the company’s proposed clinical trial design studying Xifaxan for irritable […]
When Salix Pharmaceuticals (NASDAQ:SLXP) disclosed that the U.S. Food and Drug Administration would not approve its drug Xifaxan for the new indication of irritable bowel syndrome, the gastrointestinal treatments company made clear it believed its drug met all of the targets needed for approval. Now we’re starting to see how much more ground the drug […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Salix Pharmaceuticals‘ (NASDAQ:SLXP) drug partner Napo Pharmaceuticals has terminated the collaboration agreement between the two companies over Salix’s failure to advance a promising anti-diarrhea drug for AIDS patients fast enough for the California company. Termination of the collaboration to develop the drug candidate crofelemer was effective Nov. 4 — a year to the date of […]
Gastrointestinal treatments company Salix Pharmaceuticals (NASDAQ:SLXP) will acquire Oceana Therapeutics for $300 million cash in a deal that brings two more products to its portfolio — both of them medical devices. Morrisville, North Carolina-based Salix announced the deal after the close of the financial markets and discussed the acquisition during its third quarter conference call. […]
The U.S. Food and Drug Administration will review a constipation drug marketed by Salix Pharmaceuticals (NASDAQ:SLXP) to consider adding a new indication for the product. Relistor is an injectable drug approved in 2008 to treat constipation in seriously ill patients who take pain-killing opioid medication. Opioids relieve pain by acting on receptors in the spinal […]
Salix Pharmaceuticals (NASDAQ:SLXP) needs another clinical study on its irritable bowel syndrome treatment, which means it could take two more years for the drug to secure regulatory approval. That’s two more years than the gastrointestinal therapeutics company planned for. Salix expected to get U.S. Food and Drug Administration approval for the drug Xifaxan in the […]
Three years ago, Salix Pharmaceuticals (NASDAQ:SLXP) licensed a promising compound with the goal of developing a new treatment for chronic diarrhea in HIV patients. Morrisville, North Carolina-based Salix paid Napo Pharmaceuticals $5 million up front and pledged up to $300 million in milestone payments. But now Napo Pharmaceuticals wants to get out of the deal […]
